Civantos F - Search Results

1

Does finasteride alter the pathology of the prostate and cancer grading?

Bostwick DG, Qian J, Civantos F, Roehrborn CG, Montironi R. Bostwick DG, et al. Among authors: civantos f. Clin Prostate Cancer. 2004 Mar;2(4):228-35. doi: 10.3816/cgc.2004.n.004. Clin Prostate Cancer. 2004. PMID: 15072606 Review.

2

The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.

Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, Roehrborn CG. Andriole G, et al. Among authors: civantos f. J Urol. 2005 Dec;174(6):2098-104. doi: 10.1097/01.ju.0000181216.71605.38. J Urol. 2005. PMID: 16280736 Review.

3

Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.

Civantos F, Marcial MA, Banks ER, Ho CK, Speights VO, Drew PA, Murphy WM, Soloway MS. Civantos F, et al. Cancer. 1995 Apr 1;75(7):1634-41. doi: 10.1002/1097-0142(19950401)75:7<1634::aid-cncr2820750713>3.0.co;2-#. Cancer. 1995. PMID: 8826921 Clinical Trial.

4

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA Jr, Thompson IM. Lucia MS, et al. Among authors: civantos f. J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83. doi: 10.1093/jnci/djm117. Epub 2007 Sep 11. J Natl Cancer Inst. 2007. PMID: 17848673 Clinical Trial.

5

Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer.

Ekici S, Cerwinka WH, Duncan R, Gomez P, Civantos F, Soloway MS, Lokeshwar VB. Ekici S, et al. Among authors: civantos f. Int J Cancer. 2004 Oct 20;112(1):121-9. doi: 10.1002/ijc.20368. Int J Cancer. 2004. PMID: 15305383

6

Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer.

Posey JT, Soloway MS, Ekici S, Sofer M, Civantos F, Duncan RC, Lokeshwar VB. Posey JT, et al. Among authors: civantos f. Cancer Res. 2003 May 15;63(10):2638-44. Cancer Res. 2003. PMID: 12750291

7

Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.

Cohen BL, Gomez P, Omori Y, Duncan RC, Civantos F, Soloway MS, Lokeshwar VB, Lokeshwar BL. Cohen BL, et al. Among authors: civantos f. Int J Cancer. 2006 Sep 1;119(5):1082-7. doi: 10.1002/ijc.21749. Int J Cancer. 2006. PMID: 16557596

8

Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate-specific antigen.

Soloway MS, Hachiya T, Ruiz HE, Gomez CC, Civantos F. Soloway MS, et al. Among authors: civantos f. World J Urol. 1993;11(4):221-6. doi: 10.1007/BF00185074. World J Urol. 1993. PMID: 7508788 Clinical Trial.

9

Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide.

Braslis KG, Davi RC, Nelson E, Civantos F, Soloway MS. Braslis KG, et al. Among authors: civantos f. Urology. 1995 Feb;45(2):329-31. doi: 10.1016/0090-4295(95)80028-x. Urology. 1995. PMID: 7855985

10

Histopathological effects of androgen deprivation in prostatic cancer.

Civantos F, Soloway MS, Pinto JE. Civantos F, et al. Semin Urol Oncol. 1996 May;14(2 Suppl 2):22-31. Semin Urol Oncol. 1996. PMID: 8725888 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

131 results

Search Page

Filters